The Customer

Humanigen is a US based biopharmaceutical company, with immunology and immuno-oncology portfolio of monoclonal antibodies. Within their broad portfolio, Humanigen was underway with their positive Phase 3 Clinical Trial (LIVE-AIR) for their drug lenzilumab, which was being used in newly hospitalized COVID-19 patients. Humanigen desired to quickly increase trial participants from 300 to 520.


  1. Short time window to increase recruitment of patients for drug trial from 300 to 520
  2. Identifying relevant trial participants from the high volume of generic website traffic
  3. Promotion restrictions due to ongoing US election campaigns
  4. Building credibility with patients and caregivers to participate in the trial

The Solution

We augmented traditional CRO model with digital strategies, AI/ML applications, and medical data mining for precise and effective targeting. Engaging data-driven digital campaigns were deployed for diverse patient recruitment based on geography, demography and interest-based signals. 

Hyperlocal campaigns in English and Spanish on search and social platforms with programmatic, lookalike, and re-targeting formats were activated for better reach and engagement among diverse patient and HCP pool. We used our in-house omnichannel CRM platform, built in partnership with Microsoft, for NPI-level HCP outreach geo-fenced within 50 miles of trial sites.

Humanigen propels Covid-19 trial recruitment with AI/ML-based geofenced targeting
Weekly unique visitors to trial landing page
Qualification rate through primary screening process
Participants qualified for secondary screening
Humanigen propels Covid-19 trial recruitment with AI/ML-based geofenced targeting


Humanigen was able to achieve higher engagement and enrollments of patients for the trial owing to wider reach, precise targeting, and multi-lingual campaigns.

It received over 17,000 weekly unique visitors to trial landing page and qualified 7% patients through a primary screening process, resulting in 460 participants, qualified for secondary screening